UA129793C2 - Антитіло до фактора згортання xi - Google Patents

Антитіло до фактора згортання xi

Info

Publication number
UA129793C2
UA129793C2 UAA201900311A UAA201900311A UA129793C2 UA 129793 C2 UA129793 C2 UA 129793C2 UA A201900311 A UAA201900311 A UA A201900311A UA A201900311 A UAA201900311 A UA A201900311A UA 129793 C2 UA129793 C2 UA 129793C2
Authority
UA
Ukraine
Prior art keywords
amino acid
antibody
acid sequence
sequence shown
seq
Prior art date
Application number
UAA201900311A
Other languages
English (en)
Ukrainian (uk)
Inventor
Чжу Чень
Кеннет П. Еллсворт
Кеннет П. ЭЛЛСВОРТ
Джеймс Мілліган
Джеймс Миллиган
Елізабет Олдхем
Элизабет Олдхем
Дітмар Сейфферт
Дитмар СЕЙФФЕРТ
Вайшнаві Ганті
Вайшнави ГАНТИ
Мохаммад Табрізіфард
Мохаммад ТАБРИЗИФАРД
Б'янка Прінц
Бьянка ПРИНЦ
Original Assignee
Мерк Шарп Енд Доум Елелсі
Мерк Шарп Энд Доум Элэлси
АДІМАБ, ЕлЕлСі
АДИМАБ, ЭлЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мерк Шарп Енд Доум Елелсі, Мерк Шарп Энд Доум Элэлси, АДІМАБ, ЕлЕлСі, АДИМАБ, ЭлЭлСи filed Critical Мерк Шарп Енд Доум Елелсі
Publication of UA129793C2 publication Critical patent/UA129793C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
UAA201900311A 2016-06-14 2017-06-12 Антитіло до фактора згортання xi UA129793C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662349888P 2016-06-14 2016-06-14
PCT/US2017/036940 WO2017218371A1 (en) 2016-06-14 2017-06-12 Anti-coagulation factor xi antibodies

Publications (1)

Publication Number Publication Date
UA129793C2 true UA129793C2 (uk) 2025-08-06

Family

ID=59078269

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201900311A UA129793C2 (uk) 2016-06-14 2017-06-12 Антитіло до фактора згортання xi

Country Status (29)

Country Link
US (6) US10676536B2 (https=)
EP (1) EP3469002A1 (https=)
JP (2) JP7022081B2 (https=)
KR (2) KR102218714B1 (https=)
CN (2) CN109476758B (https=)
AR (1) AR108717A1 (https=)
AU (3) AU2017286432B2 (https=)
BR (1) BR112018075858A2 (https=)
CA (2) CA3025869C (https=)
CL (2) CL2018003565A1 (https=)
CO (1) CO2018013434A2 (https=)
CR (1) CR20180583A (https=)
DO (1) DOP2018000284A (https=)
EA (1) EA201892716A1 (https=)
EC (1) ECSP18091593A (https=)
GE (2) GEP20227382B (https=)
IL (2) IL263272B2 (https=)
JO (1) JOP20180121A1 (https=)
MA (1) MA45234A (https=)
MX (2) MX2018015757A (https=)
MY (1) MY201852A (https=)
NI (1) NI201800134A (https=)
PE (1) PE20190416A1 (https=)
PH (1) PH12018502586A1 (https=)
SG (2) SG11201810763TA (https=)
TN (1) TN2018000417A1 (https=)
TW (2) TWI802193B (https=)
UA (1) UA129793C2 (https=)
WO (1) WO2017218371A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY36751A (es) 2015-06-26 2017-01-31 Novartis Ag Anticuerpos de factor xi y métodos de uso
TW201802121A (zh) 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
IL263272B2 (en) 2016-06-14 2025-07-01 Merck Sharp & Dohme Antibodies to coagulation factor xi
IL267538B2 (en) 2016-12-23 2024-05-01 Novartis Ag Antibodies against factor XI and methods for use in preventing, treating, managing or reducing the risk of thromboembolic disorder or stroke in a patient
CN110423278B (zh) * 2019-08-08 2020-07-17 上海博槿生物科技有限公司 一种抗凝血因子XI活化形式因子XIa的抗体及其制备方法和应用
EP4177274A4 (en) * 2020-07-02 2024-04-03 Beijing Tuo Jie Biopharmaceutical Co. Ltd. Anti-fxi/fxia antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
CA3188566A1 (en) * 2020-07-03 2022-01-06 Suzhou Alphamab Co., Ltd. Coagulation factor xi (fxi) binding protein
IL304971A (en) 2021-02-09 2023-10-01 Arxx Therapeutics As Humanized anti-S100A4 antibody, uses and methods
US20250034277A1 (en) * 2021-11-30 2025-01-30 Suzhou Alphamab Co., Ltd. Method for preventing and/or treating thromboembolic diseases
EP4644426A1 (en) * 2022-12-30 2025-11-05 Gan & Lee Pharmaceuticals Co., Ltd. Antibody against coagulation factor xi and/or activated form factor xia thereof, and use thereof
WO2025130748A1 (zh) * 2023-12-22 2025-06-26 四川科伦博泰生物医药股份有限公司 一种抗凝血因子XI/XIa抗体制剂

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
EP0420937B1 (en) 1988-06-21 1994-11-09 Genentech, Inc. Therapeutic compositions for the treatment of myocardial infarction
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
DE69232137T2 (de) 1991-11-25 2002-05-29 Enzon Inc Multivalente antigen-bindende proteine
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
JPH0656382A (ja) 1992-08-04 1994-03-01 Kawasaki Steel Corp コークス乾式消火装置のバケット巻上機の吊ビーム装置
MA24512A1 (fr) 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose
GB9818110D0 (en) 1998-08-19 1998-10-14 Weston Medical Ltd Needleless injectors and other devices
US6096002A (en) 1998-11-18 2000-08-01 Bioject, Inc. NGAS powered self-resetting needle-less hypodermic jet injection apparatus and method
JP2002531466A (ja) 1998-12-01 2002-09-24 プロテイン デザイン ラブス， インコーポレイテッド γ−インターフェロンに対するヒト化抗体
BRPI0108923B8 (pt) 2000-03-03 2021-05-25 Cambridge Antibody Tech Limited elemento de ligação específico, ácido nucleico isolado, célula hospedeira, métodos para produzir um elemento de ligação específico ou domínio vh ou vl de anticorpo, e, para obter um elemento de ligação específico que liga eotaxina
EP1532175B1 (en) 2002-03-22 2012-10-17 Aprogen, Inc. Humanized antibody and process for preparing the same
CN102408483B (zh) 2003-07-15 2016-06-08 安姆根有限公司 作为选择性ngf途径抑制剂的人抗ngf中和抗体
SG158150A1 (en) 2004-12-21 2010-01-29 Centocor Inc Anti-il-12 antibodies, epitopes, compositions, methods and uses
US8318906B2 (en) 2005-04-15 2012-11-27 The Regents Of The University Of California EMP2 antibodies and their therapeutic uses
RU2494107C2 (ru) 2005-05-09 2013-09-27 Оно Фармасьютикал Ко., Лтд. Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
EA017812B1 (ru) 2005-12-08 2013-03-29 Медарекс, Инк. Выделенное моноклональное антитело или его антигенсвязывающий участок, которые связываются с протеинтирозинкиназой 7 ( ptk7) человека, и их применение
US8383118B2 (en) 2005-12-08 2013-02-26 Medarex, Inc. Human monoclonal antibodies to fucosyl-GM1 and methods for using anti-fucosyl-GM1
US7960518B2 (en) 2006-06-06 2011-06-14 Crucell Holland B.V. Human binding molecules having killing activity against enterococci and uses thereof
TW200815474A (en) 2006-08-03 2008-04-01 Astrazeneca Ab Antibodies alphaVbeta6 and uses thereof
CL2007002567A1 (es) 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
CA2680741A1 (en) 2007-03-22 2009-01-15 The Regents Of The University Of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
GB0708585D0 (en) 2007-05-03 2007-06-13 Queen Mary & Westfield College Novel antibody and use in diagnosis and therapy of arthropathies
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
US8691730B2 (en) 2007-09-14 2014-04-08 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
TW200927761A (en) 2007-09-26 2009-07-01 U3 Pharma Ag Heparin-binding epidermal growth factor-like growth factor antigen binding proteins
PT3002298T (pt) * 2007-11-21 2019-11-20 Univ Oregon Health & Science Anticorpos monoclonais anti-fator xi e métodos de utilização dos mesmos
AU2016203944A1 (en) 2007-11-21 2016-07-07 Oregon Health & Science University Anti-factor xi monoclonal antibodies and methods of use thereof
US8188235B2 (en) 2008-06-18 2012-05-29 Pfizer Inc. Antibodies to IL-6 and their uses
WO2009154461A1 (en) 2008-06-19 2009-12-23 Prothix Bv Use of anti-factors xi antibodies for prevention of thrombus formation
WO2010014854A2 (en) 2008-07-31 2010-02-04 The Regents Of The University Of California Antibodies that neutralize botulinum neurotoxins
PE20110808A1 (es) 2008-10-31 2011-10-31 Janssen Biotech Inc Anticuerpos contra el receptor 3 de tipo toll
DK2356270T3 (da) 2008-11-07 2016-12-12 Fabrus Llc Kombinatoriske antistofbiblioteker og anvendelser deraf
US9212223B2 (en) 2008-11-25 2015-12-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US9452227B2 (en) 2008-11-25 2016-09-27 Alderbio Holdings Llc Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
US8388959B2 (en) 2008-12-18 2013-03-05 Oregon Health & Science University Anti-fXI antibodies and methods of use
WO2010072740A2 (en) 2008-12-23 2010-07-01 Astrazeneca Ab TARGETED BINDING AGENTS DIRECTED TO α5β1 AND USES THEREOF
EP2408814B1 (en) 2009-03-20 2018-11-21 Amgen Inc. Carrier immunoglobulins and uses thereof
US8722860B2 (en) 2009-04-16 2014-05-13 Abbvie Biotherapeutics Inc. Anti-TNF-α antibodies and their uses
US8492119B2 (en) 2009-04-27 2013-07-23 Kyowa Hakko Kirin Co., Ltd Antibody to human IL-3 receptor alpha chain
CA2777226A1 (en) 2009-10-12 2011-04-21 Pfizer Inc. Cancer treatment
CA2780221A1 (en) 2009-11-04 2011-05-12 Fabrus Llc Methods for affinity maturation-based antibody optimization
US9045536B2 (en) 2009-12-23 2015-06-02 Merck Sharp & Dohme Corp. Cell line 3M
EP2532151A2 (en) * 2010-02-03 2012-12-12 Trilogy IP Holdings, Inc. Mobile communication plan offerings
DK2593594T3 (en) 2010-07-16 2017-12-11 Adimab Llc ANTIBODY LIBRARIES
AU2011286407A1 (en) 2010-08-06 2013-02-21 Amgen Use of HER3 binding agents in prostate treatment
SG10201509499RA (en) 2010-11-19 2015-12-30 Eisai R&D Man Co Ltd Neutralizing anti-ccl20 antibodies
CA2823776A1 (en) 2011-01-06 2012-07-12 Dyax Corp. Plasma kallikrein binding proteins
KR20140033029A (ko) 2011-04-01 2014-03-17 메모리얼 슬로안-케터링 캔서 센터 에이치엘에이 에이2에 의해 제공된 더블유티1 펩타이드에 특이적인 티 세포 수용체 유사 항체
PL2718322T3 (pl) 2011-06-06 2019-07-31 Novo Nordisk A/S Lecznicze przeciwciała
US8765385B2 (en) 2011-10-27 2014-07-01 Ravindra Kumar Method of detection of neutralizing anti-actriib antibodies
EP2650310B1 (en) 2012-04-13 2016-06-08 Rottapharm Biotech S.r.l. Anti-ADAMTS-5 antibody, derivatives and uses thereof
EP2847228B1 (en) 2012-05-10 2018-07-25 Bayer Pharma Aktiengesellschaft Antibodies capable of binding to the coagulation factor xi and/or its activated form factor xia and uses thereof
WO2013173255A2 (en) 2012-05-17 2013-11-21 Sorrento Therapeutics Inc. Antigen binding proteins that bind egfr
US20140004121A1 (en) 2012-06-27 2014-01-02 Amgen Inc. Anti-mesothelin binding proteins
US9498532B2 (en) 2013-03-13 2016-11-22 Novartis Ag Antibody drug conjugates
AU2014331118B2 (en) 2013-10-01 2019-07-25 Medimmune Limited Methods of treating and diagnosing alpha-V-beta-6 overexpressing cancer
WO2015141826A1 (ja) 2014-03-20 2015-09-24 国立感染症研究所長が代表する日本国 Ｃ型肝炎ウイルスに対する感染阻害活性を有する抗体
KR101753553B1 (ko) 2014-06-03 2017-07-03 엑스바이오테크, 인크. 스타필로코커스 아우레우스 감염의 치료 및 예방을 위한 조성물 및 방법
EP3177322A4 (en) 2014-08-08 2018-07-18 Alector LLC Anti-trem2 antibodies and methods of use thereof
US9139653B1 (en) 2015-04-30 2015-09-22 Kymab Limited Anti-human OX40L antibodies and methods of treatment
CN107708733B (zh) 2015-04-07 2022-11-15 艾利妥 抗分拣蛋白抗体和其使用方法
JP7497953B2 (ja) 2015-06-12 2024-06-11 アレクトル エルエルシー 抗ｃｄ３３抗体及びその使用方法
UY36751A (es) 2015-06-26 2017-01-31 Novartis Ag Anticuerpos de factor xi y métodos de uso
WO2017015619A1 (en) 2015-07-23 2017-01-26 The Regents Of The University Of California Antibodies to coagulation factor xia and uses thereof
CA2997444A1 (en) 2015-09-29 2017-04-06 Amgen Inc. Asgr inhibitors for reducing cholesterol levels
TWI736575B (zh) 2016-01-22 2021-08-21 美商默沙東藥廠 抗凝固因子ｘｉ抗體
IL263272B2 (en) 2016-06-14 2025-07-01 Merck Sharp & Dohme Antibodies to coagulation factor xi
MX2019003077A (es) 2016-09-20 2020-02-05 Bayer Pharma AG Anticuerpos novedosos contra el factor xi y sus usos.

Also Published As

Publication number Publication date
JP7022081B2 (ja) 2022-02-17
EA201892716A1 (ru) 2019-05-31
TW201802120A (zh) 2018-01-16
CA3025869C (en) 2025-10-07
US11485794B2 (en) 2022-11-01
DOP2018000284A (es) 2019-01-31
IL315266A (en) 2024-10-01
PE20190416A1 (es) 2019-03-19
US11661460B2 (en) 2023-05-30
IL263272A (en) 2018-12-31
GEAP202114983A (en) 2021-12-10
US20200270364A1 (en) 2020-08-27
GEP20227382B (en) 2022-05-25
AU2020210233A1 (en) 2020-08-20
US20170355780A1 (en) 2017-12-14
WO2017218371A1 (en) 2017-12-21
ECSP18091593A (es) 2019-01-31
AR108717A1 (es) 2018-09-19
AU2017286432A1 (en) 2018-12-06
IL263272B1 (en) 2025-03-01
CL2018003565A1 (es) 2019-03-22
US10676536B2 (en) 2020-06-09
US20230287141A1 (en) 2023-09-14
KR20210021124A (ko) 2021-02-24
MX2023012740A (es) 2024-02-23
CA3025869A1 (en) 2017-12-21
CN116425879A (zh) 2023-07-14
CO2018013434A2 (es) 2018-12-28
JP7277500B2 (ja) 2023-05-19
TN2018000417A1 (en) 2020-06-15
SG10202103120UA (en) 2021-05-28
JOP20180121A1 (ar) 2018-12-12
PH12018502586A1 (en) 2019-10-07
MA45234A (fr) 2019-04-17
US20200255542A1 (en) 2020-08-13
US20200308302A1 (en) 2020-10-01
BR112018075858A2 (pt) 2019-04-02
US12275800B2 (en) 2025-04-15
CA3172367A1 (en) 2017-12-21
JP2019521978A (ja) 2019-08-08
CN109476758A (zh) 2019-03-15
AU2024201084A1 (en) 2024-03-14
CN109476758B (zh) 2023-05-23
IL263272B2 (en) 2025-07-01
NZ748743A (en) 2025-06-27
AU2020210233B2 (en) 2024-03-07
US11512142B2 (en) 2022-11-29
NZ786448A (en) 2025-06-27
NI201800134A (es) 2019-03-05
KR102379580B1 (ko) 2022-03-29
US11479615B2 (en) 2022-10-25
AU2017286432B2 (en) 2020-09-24
TWI752964B (zh) 2022-01-21
US20200317811A1 (en) 2020-10-08
EP3469002A1 (en) 2019-04-17
NZ786443A (en) 2025-06-27
NZ786444A (en) 2025-06-27
MY201852A (en) 2024-03-20
CR20180583A (es) 2019-07-02
NZ786442A (en) 2025-06-27
TW202214702A (zh) 2022-04-16
MX2018015757A (es) 2019-05-30
CL2024000367A1 (es) 2024-08-23
KR102218714B1 (ko) 2021-02-24
TWI802193B (zh) 2023-05-11
KR20190018504A (ko) 2019-02-22
SG11201810763TA (en) 2018-12-28
JP2021101720A (ja) 2021-07-15
NZ786447A (en) 2025-06-27

Similar Documents

Publication Publication Date Title
UA129793C2 (uk) Антитіло до фактора згортання xi
UA124734C2 (uk) Антитіло проти с5 і його застосування
UA120596C2 (uk) Моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
UA126281C2 (uk) Антитіла проти сигнал-регуляторного білка альфа та способи їх застосування
UA125501C2 (uk) Моноклональне антитіло, або його антигензв'язувальний фрагмент, яке здатне специфічно зв'язуватися з альфа-синуклеїном людини, його застосування та спосіб лікування синуклеопатії
ES2828739T3 (es) Anticuerpos que se unen a la proteína tirosina fosfatasa beta humana (HPTP-beta) y sus usos
UA126441C2 (uk) Химерні антигенні рецептори, націлені на bcma, та способи їх застосування
UA126972C2 (uk) Аденовірус, озброєний біспецифічним рекрутером t-клітин (bite)
UA123763C2 (uk) Фармацевтична композиція для контролю або лікування захворювання або порушення, пов’язаного з fgf19
UA128669C2 (uk) ГЕТЕРОДИМЕРНИЙ Fc-ЗЛИТИЙ БІЛОК IL15/IL15Ra
UA127495C2 (uk) Виділений антигензв'язуючий білок, який специфічно зв'язується з поліпептидом рецептора шлункового інгібіторного пептиду (gipr) людини, та фармацевтична композиція, яка його містить
UA124615C2 (uk) АНТИТІЛО ПРОТИ ПОДІБНОГО ДО Fc-РЕЦЕПТОРА БІЛКА 5 (FcRH5)
UA129471C2 (uk) Білки, які містять антигензв'язувальні домени пов'язаної з калікреїном пептидази 2, і їх застосування
CN109152834A (zh) 抑制有需要的受试者的血管发生的方法
UA103912C2 (uk) Антитіла проти ангіопоетину-2 людини
UA125577C2 (uk) Антигензв'язуюча молекула, які містить тримерний ліганд сімейства tnf
UA127308C2 (uk) Активована протеазою біспецифічна молекула, яка зв'язує т-клітини
UA126964C2 (uk) Конструкція біспецифічного антитіла, що зв'язується з дпб3 (dll3) і кд3 (cd3)
UA126561C2 (uk) Застосування антитіла проти с5
UA126549C2 (uk) Композиція і спосіб для з'єднання позаклітинних доменів типу і та типу іі як гетерологічного химерного білка
UA118749C2 (uk) Конструкція антитіла до cdh19 і cd3
UA119226C2 (uk) Антитіло, яке специфічно зв'язується з axl, та його застосування як продукту для адресної доставки при лікуванні раку
UA125718C2 (uk) Композиції антитіл до ror1 і пов'язані з ними способи
UA120753C2 (uk) Біспецифічне антитіло до сd3 та cd20
UA127339C2 (uk) СПОСІБ ПРОФІЛАКТИКИ АБО ЗМЕНШЕННЯ УРАЖЕННЯ НИРОК У СУБ'ЄКТА, ЩО СТРАЖДАЄ НА СТЕРОЇДЗАЛЕЖНУ ІМУНОГЛОБУЛІН-А-НЕФРОПАТІЮ (IgAN)